HOME >> BIOLOGY >> NEWS
JCI table of contents, 16 August, 2004

t of the means to evade the MIC activated immune surveillance system may be a mechanism for prostate cancer progression, that soluble MIC measurement may be a useful biomarker for disease progression, and that cytokine treatment may aid in reestablishing natural killer cell anti-tumor activity.

TITLE: Prevalent expression of the immunostimulatory MHC class I chainrelated molecule is counteracted by shedding in prostate cancer

AUTHOR CONTACT:
Jennifer D. Wu University of Washington, 325 9th Ave., Seattle, WA 98104, USA
Phone: (206) 341-5349; Fax: (206) 341-5302. E-mail: wuj@u.washington.edu

View the PDF of this article at: https://www.the-jci.org/press/22206.pdf


Having an Affinity for Diabetes

Insulin autoantibodies (IAAs) are often the first antibodoies directed against self that are recognized in the natural history of childhood diabetes. Not all IAA-positive children, however, go on to develop additional autoantibodies against antigens from pancreas islet cells and, from there, progress to type 1 diabetes mellitus (T1DM). In a standard immune response, antibody maturation through repeated exposure to antigen results in increased antibody affinity. Ezio Bonifacio and colleagues, from the Diabetes Research Institute in Germany, analyzed IAA affinity in IAA-positive samples from children of the BABYDIAB cohort to examine the relationship of antibody affinity to development of T1DM. Using a competitive radiobinding assay, the authors found that the presence of high-affinity IAAs in a sample correlated with the individual having HLA DRB1*04 and subsequently developing multiple islet autoantibodies and T1DM. In examining epitope specificity, they further found that high- and low-affinity IAAs were reactive with different insulin epitopes and that high-affinity IAAs were reactive with (pro)insulin, whi
'"/>

Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
16-Aug-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 2 August, 2004
7. When male fish hum, females swim in, thanks to hormones, adaptable hearing
8. JCI table of contents, 1 July 2004
9. Search and destroy protein turns tables on HIV
10. JCI table of contents, 15 June 2004
11. JCI table of contents, 1 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
Cached News: